Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 2, 2010, Pages 252-260

  Campo, Aránzazu ^a   Mathai, Stephen C ^a   Le Pavec, Jérôme ^a   Zaiman, Ari L ^a   Hummers, Laura K ^a   Boyce, Danielle ^a   Housten, Traci ^a   Champion, Hunter C ^a   Lechtzin, Noah ^a   Wigley, Fredrick M ^a   Girgis, Reda E ^a   Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID;

ARTERIAL OXYGEN SATURATION; ARTICLE; CAPACITANCE BLOOD VESSEL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY FUNCTION; LUNG ARTERY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SYSTEMIC SCLEROSIS; COHORT ANALYSIS; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; HOSPITALIZATION; KAPLAN MEIER METHOD; LUNG CIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PHYSIOLOGY; VASCULAR RESISTANCE;

COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERICARDIAL EFFUSION; PULMONARY CIRCULATION; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION;

EID: 77956632784     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200912-1820OC     Document Type: Article

References (50)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-944.
2. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-524.
3. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-993.
4. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-350.
5. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-932.
6. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs SR, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-157.
7. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-3050.
8. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009;36:2244-2249.
9. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008;117:2475-2483.
10. Mathai SC, Bueso M, Hummers LK, Boyce D, Lechtzin N, Le Pavec J, Campo A, Champion HC, Housten T, Forfia PR, et al. Disproportionate elevation of NT-proBNP in scleroderma-related pulmonary hypertension. Eur Respir J 2010;35:95-104.
11. Campo A, Mathai SC, Zaiman A, Champion HC, Housten T, Boyce DM, Lechtzin N, Hummers L, Wigley F, Girgis RE, et al. Survival of pulmonary arterial hypertension related to systemic sclerosis: a single center longitudinal study. Am J Respir Crit Care Med 2009;179:A2657.
12. Campo A, Mathai SC, Girgis RE, Zaiman AL, Hummers L, Wigley F, Hassoun PM. Hemodynamic predictors of survival in scleroderma related pulmonary hypertension: a single center study. Presented at the annual international meeting for the European Respiratory Society. September 12-16, 2009, Vienna, Austria.
13. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
14. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007;66:1467-1472.
15. Her C. Right ventricular stroke-work. An index of distribution of pulmonary perfusion in acute respiratory failure. Chest 1983;84:719-724.
16. Levey AS. Greene T, Kusek J, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000;11:A0828.
17. Van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, Postmus PE, Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:1250-1257.
18. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006;47:799-803.
19. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG, Marques KM, Smit EF, Dijkmans BA, Vonk-Noordegraaf A. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.Eur Respir J 2008;31:1160-1166.
20. Kawut SM, Al-Naamani N, Agestrand C, Rosenzweig EB, Rowan C, Barst RJ, Bergmann S, Horn EM. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 2009;135:752-759.
21. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;110:1308-1312.
22. Henkens I, Van Wolferen S, Gan C, Boonstra A, Swenne C, Twisk J, Kamp O, van der Wall E, Schalij M, Vonk-Noordegraaf A. Relationship of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2009;103:1451-1456.
23. Fernandes F, Alvarez Ramires FJ, Arteaga E, Ianni BM, Oliveira Bonfá ESD, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003;9:311-317.
24. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol 2006;33:2464-2469.
25. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, Gialafos EJ, Moyssakis I, Moutsopoulos HM. Pattern and distribution of myocardial fibrosis in systemic sclerosis. Arthritis Rheum 2007;56:3827-3836.
26. Bezante GP, Rollando D, Sessarego M, Panico N, Setti M, Filaci G, Molinari G, Balbi M, Cutolo M, Barsotti A, et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007;34:2431-2437.
27. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Hatron PY, Beregi JP, Hachulla E. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-1884.
28. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, Chamera E, Corretti MC, Champion HC, Abraham TP, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-1041.
29. Huez S, Roufosse F, Vachiery JL, Pavelescu A, Derumeaux G, Wautrecht JC, Cogan E, Naeije R. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J 2007;30:928-936.
30. Meune C, Allanore Y, Pascal O, Devaux JY, Dessault O, Duboc D, Weber S, Kahan A. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 2005;6:351-357.
31. Lindqvist P, Caidahl K, Neuman-Andersen G, Ozolins C, Rantapää-Dahlqvist S, Waldenström A, Kazzam E. Disturbed right ventricular diastolic function in patients with systemic sclerosis. A Doppler tissue imaging study. Chest 2005;128:755-763.
32. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Guillevin L, Kahan A, Allanore Y. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care. A controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-1809.
33. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78-92.
34. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-577.
35. Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2006;19:1045-1050.
36. Lankhaar JW, Westerhof N, Faes TJC, Marques KMJ, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol 2006;291:H1731-H1737. (Pubitemid 44497678)
37. Gan CTJ, Lankhaar JW, Westerhof N, Marcus JT, Becker A, Twisk JWR, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007;132:1906-1912.
38. Lankhaar J-W, Westerhof N, Faes TJC, Gan CT, Marques KM, Boonstra A, van den Berg FG, Postmus PE, Vonk-Noordegraaf A. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J 2008;29:1688-1695.
39. Sanz J, Kariisa M, Dellegrottaglie S, Prat-González S, Garcia MJ, Fuster V, Rajagopalan S. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging 2009;2:286-295.
40. Ioannidis JPA, Vlachoyannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, te Boome L, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
41. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, et al. The registry of the German Network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008;47:1185-1192.
42. Scheja A, Bartosik I, Wuttge DM, Hesselstrand R. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009;38:295-298.
43. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidente, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-2255.
44. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-1996.
45. Ruiz-Cano MJ, Escribano P, Alonso R, Delgado J, Carreira P, Velázquez T, Sánchez MA, Sáenz de la Calzada C. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension. J Heart Lung Transplant 2009;28:621-627.
46. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
47. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakian C, Yaici A, Achouh L, Parent F, Jais X, Simonneau G, et al. Long-term outcome of systemic sclerosis associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 2010;49:490-500.
48. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000;132:425-434.
49. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009;36:330-336.
50. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End points and clinical trial designs in pulmonary hypertension. Clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43(12 suppl S)48S-55S.